Welcome to our dedicated page for Cosmos Holdings news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Holdings stock.
Cosmos Health Inc, also known as Cosmos Health, is a global healthcare group engaged in innovative R&D, pharmaceuticals & nutraceuticals manufacturing, and healthcare product distribution. The company owns proprietary brands like Sky Premium Life and Mediterranation, providing a wide range of products to healthcare providers. In recent news, the acquisition of Pelofarm's pharmacy distribution network in Greece shows Cosmos Health's strategic expansion and revenue growth.
Rhea-AI Summary
Cosmos Health Inc. receives a Speculative Buy rating and a $4.00 price target from Taglich Brothers, indicating substantial growth potential. The company's revenue is expected to reach $64 million in FY 2024, with a focus on vertical integration and global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. CEO, Mr. Greg Siokas, demonstrates his confidence in the company by acquiring 60,000 shares at $0.8301 each, totaling $49,806. Siokas plans to invest up to $3 million in shares by 2024. Despite significant company progress, Siokas believes the stock is undervalued, emphasizing commitment to enhancing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. announced that Taglich Brothers, Inc. has initiated coverage of the Company's common stock. Taglich Brothers is a full-service broker dealer with a focus on microcap companies. The coverage and associated reports will be available at www.taglichbrothers.com. Cosmos Health CEO, Greg Siokas, stated that the company has accomplished multiple milestones, including transforming its balance sheet, completing strategic acquisitions, enhancing production facilities, launching new brands, filing patent applications, and establishing a portfolio of generic drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
Rhea-AI Summary
Cosmos Health Inc. has successfully completed the acquisition of Cloudscreen, a cutting-edge AI-powered platform specialized in drug repurposing. Cloudscreen's AI algorithm integrates 1D and 3D data to provide accurate predictions for existing drugs towards new indications, offering higher success rates, heightened safety profiles, and significantly shorter impact times compared to traditional drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. has completed the acquisition of a portfolio of 10 generic drugs, enhancing its pharmaceutical portfolio. The acquisition cost €3.2 million, and the global generic drugs market is projected to reach $613.34 billion by 2030. Cosmos Health aims to capture a substantial share of this market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) expects significant revenue growth from recent acquisitions, projecting a $12.5M increase in FY 2024 group revenue, with a gross profit of at least $3.1M and EBITDA in excess of $1.3M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
News
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) announced the acquisition of the license and rights for 'DIABIT-IS X', a generic drug used in the treatment of type-2 diabetes. The drug is set to be launched in Europe following the expiration of the patent for the branded drug 'Januvia'. Cosmos Health aims to capture a significant share of the European market and generate substantial profits from this investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.33%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) CEO Greg Siokas plans to purchase up to $3 million in common shares through open market transactions, with $1 million already purchased in 2023. Siokas believes the shares are undervalued and intends to increase his stake by approximately 20% of the market capitalization. He has invested over $15 million in the company since inception and sees this as a strategic investment given the innovative R&D projects, AI-drug repurposing, planned spinoff of the R&D department, and international brand growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) CEO to participate in Invest in Greece Forum, discussing investment opportunities in the healthcare sector. Registration and 1-on-1 meetings available for institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) announced an agreement with Cloudpharm PC to acquire the rights to repurpose a drug for treating various diseases, including CNS cancers and autoimmune diseases. The global brain tumor treatment market is expected to reach $3.1 billion by 2023, with a projected CAGR of 7.2% until 2033. Cosmos Health aims to explore drug repurposing opportunities using advanced technology to deliver medicines faster and more efficiently, targeting major health disorders like cancer, diabetes, and obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
FAQ
What is the current stock price of Cosmos Holdings (COSM)?
The current stock price of Cosmos Holdings (COSM) is $0.5829 as of December 20, 2024.
What is the market cap of Cosmos Holdings (COSM)?
The market cap of Cosmos Holdings (COSM) is approximately 14.8M.
What is Cosmos Health Inc known for?
Cosmos Health Inc is a global healthcare group engaged in R&D, pharmaceuticals & nutraceuticals manufacturing, and healthcare product distribution.
What proprietary brands does Cosmos Health Inc own?
Cosmos Health Inc owns proprietary brands like Sky Premium Life and Mediterranation.
What recent development has Cosmos Health Inc made?
Recent news includes the acquisition of Pelofarm's pharmacy distribution network in Greece, showcasing strategic expansion and revenue growth.
Where does Cosmos Health Inc operate?
Cosmos Health Inc is currently expanding throughout Europe, Asia, and North America, with offices and distribution centers in Thessaloniki, Athens, and Harlow.
How is Cosmos Health Inc leveraging technology in its operations?
Cosmos Health Inc utilizes advanced technological systems like A-Frame and ROWA in its facilities for automated procurement, inventory management, and order execution.
Cosmos Holdings Inc.
Nasdaq:COSM
COSM Rankings
COSM Stock Data
14.84M
19.72M
15.51%
10.28%
1.56%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
United States of America
THESSALONIKI